Evaluating Cancer Costs in NCI Trials

Abstract

Historically, the evaluation of new, therapeutic strategies for cancer have depended exclusively on safety and clinical efficacy.[1] Today, there is an increasing recognition by health care providers and financing organizations of the resource constraints on the provision of these services, lending greater importance to their economic evaluation.[1]–[4] Further, as costs for such services continue to rise, there is also a heightened desire for information on the value for each dollar spent in providing these technologies.

Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J. 1991; 146:473–81.Google Scholar

Ihle JN. Biomedical and biological properties of interleukin-3: a lymphokine mediating the differentiation of a lineage of cells which includes prothymocytes and mast-like cells. J Immunol. 1983; 131: 282.PubMedGoogle Scholar